186
Participants
Start Date
May 26, 2025
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2028
Isuzinaxib
Oral dosing regimen once daily
Placebo
Oral dosing regimen once daily
RECRUITING
Korea University Ansan Hospital, Ansan-si
NOT_YET_RECRUITING
Inje university Busan Paik Hospital, Busan
RECRUITING
Pusan National University Hospital, Busan
RECRUITING
SoonChunHyang University Hospital Cheonan, Cheonan
RECRUITING
Keimyung University Daegu Dongsan Hospital, Daegu
RECRUITING
Inje university Ilsan Paik Hospital, Goyang-si
RECRUITING
Hanyang University Guri Hospital, Guri-si
RECRUITING
Chung-Ang University Gwangmyeong Hospital, Gwangmyeong
RECRUITING
The Catholic University of Korea Incheon St. Mary's Hospital, Incheon
NOT_YET_RECRUITING
Jeonbuk National University Hospital, Jeonju
RECRUITING
CHA Bundang Medical Center, Seongnam-si
RECRUITING
Boramae Medical Center, Seoul
RECRUITING
Korea University Guro Hospital, Seoul
RECRUITING
Kyung Hee University Hospital at Gangdon, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
RECRUITING
The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul
RECRUITING
The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu-si
NOT_YET_RECRUITING
Wonju Severance Christian Hospital, Wŏnju
RECRUITING
Pusan National University Yangsan Hospital, Yangsan
Lead Sponsor
Aptabio Therapeutics, Inc.
INDIV